Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

West Melbourne, Australia Clinical Trials

A listing of West Melbourne, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (688) clinical trials

Efficacy Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

This is a Phase 2a, double-blind, placebo-controlled, parallel group study in subjects with active ulcerative colitis and a non-remission (partial) response to infliximab. All enrolled subjects must have been on infliximab for a minimum of 14 weeks with last dose 8 weeks prior to the date of randomization. Subjects will ...

Phase

1.71 miles

Learn More »

Is Sensory Stimulation Effective in Reducing Time Spent in a Coma or Vegetative State

A randomised control trial of patients who have a severe brain injury to determine if patients who receive a standardised sensory stimulation program emerge earlier from a vegetative state. The experimental group would receive, in addition to their normal occupational therapy, sensory stimulation which would involve the daily application of ...

Phase

1.71 miles

Learn More »

Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

This is a first-in-human, open-label, phase 1, sequential dose escalation study. AMG 673 will be evaluated as a short term intravenous (IV) infusion in adult subjects with relapsed/refractory AML. The study will be conducted at approximately 7 sites in the United States, Australia and Germany.

Phase N/A

1.71 miles

Learn More »

Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)

Background: Cardiac Resynchronization Therapy (CRT) is an established treatment in heart failure (HF) patients with ventricular dyssynchrony who remain in sinus rhythm. Available clinical data has shown inferior outcomes of CRT in HF patients with co-existent atrial fibrillation (AF), who comprise up to 27% of HF patients, and are over-represented ...

Phase N/A

1.71 miles

Learn More »

An Open-Label Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C ...

Phase

1.71 miles

Learn More »

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two treatment periods. In Period A, participants are randomized to receive either risankizumab dose A, dose B, or placebo. In Period B, ...

Phase

1.71 miles

Learn More »

Safety Tolerability Pharmacokinetics and Efficacy of AMG 160 in Subjects With mCRPC

This is a phase I, first-in-human study to evaluate the safety and tolerability of AMG 160, a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody, in subjects with metastatic castration-resistant prostate cancer.

Phase

1.71 miles

Learn More »

Safety and Effectiveness of TactiCath Contact Force Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refractory Symptomatic Persistent Atrial Fibrillation

This clinical investigation is intended to demonstrate the safety and effectiveness of the TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) for use in cardiac electrophysiological mapping and for the treatment of drug-refractory, recurrent symptomatic persistent atrial fibrillation (AF) when used in conjunction with a compatible radiofrequency (RF) generator ...

Phase N/A

1.71 miles

Learn More »

Safety Tolerability PK PD and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory AML. Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase 2 dose [RP2D]). Approximately 80 subjects will be enrolled.

Phase

1.71 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD). This Phase 2 study is designed to evaluate the safety of two doses of CT1812 administered once daily for 6 months ...

Phase

1.71 miles

Learn More »